5-Methoxy-2-[(4-methylphenyl)sulfonylamino]benzoyl chloride | 474448-79-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-Methoxy-2-[(4-methylphenyl)sulfonylamino]benzoyl chloride
• CAS: 474448-79-8
• 化学式: C₁₅H₁₄ClNO₄S
• 分子量: 339.799
• InChiKey: DHRLEEITCPYEPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  80.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-(-)-1-苯丙胺 、 5-Methoxy-2-[(4-methylphenyl)sulfonylamino]benzoyl chloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 5-Methoxy-N-((S)-1-phenyl-propyl)-2-(toluene-4-sulfonylamino)-benzamide
  参考文献：
  名称：

  Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel

  摘要：

  The search for novel, potent Kv1.5 blockers based on an anthranilic amide scaffold employing a pharmacophore-based virtual screening approach is described. The synthesis and structure-activity relationships (SAR) with respect to inhibition of the Kv1.5 channel are discussed. The most potent compounds display sub-micromolar inhibition of Kv1.5 and no significant effect on the HERG channel. In addition, good oral bioavailability is demonstrated for compound X in rats. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.057
• 作为产物：
  描述：

  5-methoxy-2-((4-methylphenyl)sulfonamido)benzoic acid 在 氯化亚砜 作用下， 生成 5-Methoxy-2-[(4-methylphenyl)sulfonylamino]benzoyl chloride
  参考文献：
  名称：

  Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel

  摘要：

  The search for novel, potent Kv1.5 blockers based on an anthranilic amide scaffold employing a pharmacophore-based virtual screening approach is described. The synthesis and structure-activity relationships (SAR) with respect to inhibition of the Kv1.5 channel are discussed. The most potent compounds display sub-micromolar inhibition of Kv1.5 and no significant effect on the HERG channel. In addition, good oral bioavailability is demonstrated for compound X in rats. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.057

文献信息

• ANTHRANILAMIDES AND METHODS OF THEIR USE
  申请人：Brendel Joachim

  公开号：US20070117807A1

  公开（公告）日：2007-05-24

  The present invention is related to a process for preparing anthranilamides of formula I, in which R(1) to R(7) have the meanings indicated herein, a process for their preparation, their use as medicaments, and pharmaceutical preparations containing them. The compounds act on the Kv1.5 potassium channel and inhibit a potassium current which is referred to as the ultra-rapidly activating delayed rectifier in the atrium of the human heart. The compounds are therefore suitable for use as novel antiarrhythmic agents for the treatment and prophylaxis of atrial arrhythmias (e.g., atrial fibrillation (AF) or atrial flutter).

  本发明涉及一种制备式I的蒽酰胺的方法，其中R（1）至R（7）具有本文中所示的含义，其制备方法，作为药物的使用以及含有它们的制药制剂。该化合物对Kv1.5钾通道产生作用，并抑制被称为人类心房中超快速激活延迟整流器的钾电流。因此，该化合物适用于作为新型抗心律失常剂用于治疗和预防心房心律失常（例如心房颤动（AF）或心房扑动）。
• ANTHRANILSÄUREAMIDE, VERFAHREN ZU IHRER HERSTELLUNG, IHRE VERWENDUNG ALS ANTIARRHYTHMIKA SOWIE PHARMAZEUTISCHE ZUBEREITUNGEN DAVON
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1385820B1

  公开（公告）日：2011-10-12
• US7235690B2
  申请人：——

  公开号：US7235690B2

  公开（公告）日：2007-06-26
• US7332608B2
  申请人：——

  公开号：US7332608B2

  公开（公告）日：2008-02-19
• Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel
  作者：Stefan Peukert、Joachim Brendel、Bernard Pirard、Carsten Strübing、Heinz-Werner Kleemann、Thomas Böhme、Horst Hemmerle

  DOI：10.1016/j.bmcl.2004.03.057

  日期：2004.6

  The search for novel, potent Kv1.5 blockers based on an anthranilic amide scaffold employing a pharmacophore-based virtual screening approach is described. The synthesis and structure-activity relationships (SAR) with respect to inhibition of the Kv1.5 channel are discussed. The most potent compounds display sub-micromolar inhibition of Kv1.5 and no significant effect on the HERG channel. In addition, good oral bioavailability is demonstrated for compound X in rats. (C) 2004 Elsevier Ltd. All rights reserved.